MicroRNA-145 Post-transcriptionally Regulates the Expression and Function of P-glycoprotein in Intestinal Epithelial Cells

P-glycoprotein (P-gp/MDR1) is a multispecific efflux transporter regulating the pharmacokinetics of various drugs. Although P-gp expression in the small intestine is elevated after liver ischemia-reperfusion (I/R) injury, the regulatory mechanism remains to be clarified. MicroRNAs (miRNAs) play an important role in the post-transcriptional regulation of the expression of drug transporters. Here, we investigated the intestinal expression profile of miRNAs after liver I/R and the role of miRNAs in the post-transcriptional regulation of P-gp in intestinal epithelial cells. Microarray analysis showed that microRNA-145 (miR-145) level was decreased in the small intestine of I/R rats. This downregulation of miR-145 was further confirmed by real-time polymerase chain reaction. In silico analysis revealed that 3′-untranslated regions (UTRs) of rat Mdr1a, mouse Mdr1a, and human MDR1 mRNA retain binding sites for miR-145. Luciferase assays using MDR1 3′-UTR reporter plasmid in HEK293 cells showed that luciferase activity was decreased by the overexpression of miR-145, and the deletion of miR-145 binding site within MDR1 3′-UTR abolished this decreased luciferase activity. The downregulation of miR-145 in Caco-2 cells, an epithelial cell line derived from human colon, increased P-gp expression and efflux activity of rhodamine 123, but not MDR1 mRNA level. These findings demonstrated that miR-145 negatively regulates the expression and function of P-gp through the repression of mRNA by direct interaction on the 3′-UTR of MDR1 mRNA. In addition, the downregulation of miR-145 should significantly contribute to the elevated intestinal P-gp expression after liver I/R. Our results provide new insight into the post-transcriptional regulation of intestinal P-gp.

[1]  T. Shimada,et al.  Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. , 2006, Biochemical pharmacology.

[2]  R. Place,et al.  Transient Focal Ischemia Induces Extensive Temporal Changes in Rat Cerebral MicroRNAome , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  G. Wong,et al.  Hyaluronan-CD44 Interaction with Protein Kinase Cϵ Promotes Oncogenic Signaling by the Stem Cell Marker Nanog and the Production of MicroRNA-21, Leading to Down-regulation of the Tumor Suppressor Protein PDCD4, Anti-apoptosis, and Chemotherapy Resistance in Breast Tumor Cells* , 2009, The Journal of Biological Chemistry.

[4]  Chunxiang Zhang,et al.  MicroRNA-145, a Novel Smooth Muscle Cell Phenotypic Marker and Modulator, Controls Vascular Neointimal Lesion Formation , 2009, Circulation research.

[5]  Krista A. Zanetti,et al.  Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.

[6]  S. S. Lee,et al.  Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy. , 1999, Journal of hepatology.

[7]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[8]  G. Amidon,et al.  The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine , 2003, Journal of Pharmacology and Experimental Therapeutics.

[9]  V. Kim MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[10]  Satohiro Masuda,et al.  An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. , 2006, Pharmacology & therapeutics.

[11]  Sidhartha Hazari,et al.  Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. , 2012, The American journal of pathology.

[12]  Chunxiang Zhang,et al.  Involvement of MicroRNAs in Hydrogen Peroxide-mediated Gene Regulation and Cellular Injury Response in Vascular Smooth Muscle Cells* , 2009, Journal of Biological Chemistry.

[13]  G. Dalmasso,et al.  MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[14]  S. Masuda,et al.  Decreased expression of P-glycoprotein during differentiation in the human intestinal cell line Caco-2. , 2003, Biochemical pharmacology.

[15]  D. Keppler,et al.  Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2 , 1999, Hepatology.

[16]  Jing Cai,et al.  MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. , 2010, Gynecologic oncology.

[17]  R. Traber,et al.  Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor. , 2002, Journal of medicinal chemistry.

[18]  Ning Li,et al.  Tissue distribution and chemical induction of multiple drug resistance genes in rats. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[19]  P. Borst,et al.  Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[21]  Xiuping Liu,et al.  Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. , 2008, Biochemical pharmacology.

[22]  Y. Akao,et al.  Identification of non-coding RNAs embracing microRNA-143/145 cluster , 2010, Molecular Cancer.

[23]  M. Nakajima,et al.  MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. , 2011, Pharmacology & therapeutics.

[24]  R. Farinotti,et al.  Cyclooxygenase Inhibitors Down Regulate P-glycoprotein in Human Colorectal Caco-2 Cell Line , 2008, Pharmaceutical Research.

[25]  You Li,et al.  Regulation of hepatic microRNA expression in response to ischemic preconditioning following ischemia/reperfusion injury in mice. , 2009, Omics : a journal of integrative biology.

[26]  S. Masuda,et al.  Transient up-regulation of P-glycoprotein reduces tacrolimus absorption after ischemia-reperfusion injury in rat ileum. , 2005, Biochemical pharmacology.

[27]  Yuriy Gusev,et al.  Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. , 2007, RNA.

[28]  Shingo Takagi,et al.  MicroRNAs Regulate Human Hepatocyte Nuclear Factor 4α, Modulating the Expression of Metabolic Enzymes and Cell Cycle* , 2009, The Journal of Biological Chemistry.

[29]  A. Rane,et al.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. , 2005, British journal of clinical pharmacology.

[30]  E. Izaurralde,et al.  Getting to the Root of miRNA-Mediated Gene Silencing , 2008, Cell.

[31]  John McAnally,et al.  MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. , 2009, Genes & development.

[32]  Ulf Norinder,et al.  Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.

[33]  Shingo Takagi,et al.  Post-transcriptional Regulation of Human Pregnane X Receptor by Micro-RNA Affects the Expression of Cytochrome P450 3A4* , 2008, Journal of Biological Chemistry.

[34]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[35]  M. Fromm,et al.  Genetic polymorphisms of the human MDR1 drug transporter. , 2003, Annual review of pharmacology and toxicology.

[36]  K. Tsuneyama,et al.  Plasma MicroRNA Profiles in Rat Models of Hepatocellular Injury, Cholestasis, and Steatosis , 2012, PloS one.

[37]  Marilyn E Morris,et al.  MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.

[38]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[39]  S. Uemoto,et al.  Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. , 2002, The Journal of surgical research.

[40]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[41]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[42]  H. Matsuda,et al.  Decreased Oral Absorption of Cyclosporine A after Liver Ischemia-Reperfusion Injury in Rats: The Contribution of CYP3A and P-Glycoprotein to the First-Pass Metabolism in Intestinal Epithelial Cells , 2009, Journal of Pharmacology and Experimental Therapeutics.

[43]  Laura Beretta,et al.  Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease , 2011, PloS one.

[44]  W. Sadee,et al.  Searching for polymorphisms that affect gene expression and mRNA processing: Example ABCB1 (MDR1) , 2006, The AAPS Journal.

[45]  Koichi Inoue,et al.  Pulmonary , gastrointestinal and urogenital pharmacology An antioxidant Trolox restores decreased oral absorption of cyclosporine A after liver ischemia – reperfusion through distinct mechanisms between CYP 3 A and P-glycoprotein in the small intestine , 2012 .